ISSN: 2277-1891

International Journal of Advance Innovations, Thoughts & Ideas



Potential of KLS-13019 to Serve as Non-Addicting and Non-Opioid Option for Neuropathic and Chronic Pain Relief

Dean Petkanas Kannalife, Inc., USA

According to the White House drug policy office, drug-related fatalities increased by 11.4% year-over-year in the first four months of 2020. As opioid overdose deaths skyrocket across the U.S. during the COVID-19 pandemic, emphasis needs to be placed on proactively creating non-opioid solutions for pain relief. Kannalife, Inc., a biopharmaceutical and